NeuBase Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

NeuBase Therapeutics

17/12/2021 21:44

* NeuBase Therapeutics Inc  NBSE.OQ   NBSE.O  is expected
to show no change in quarterly revenue when it reports 
results on December 21 (estimated). 
​* Refinitiv's mean analyst estimate for NeuBase Therapeutics
Inc is for a loss of 23 cents per share. For the same quarter
last year, the company reported a loss of 19 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $16​, about 83.8% above​ its last closing
price of $2.60. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  -0.22       -0.21      -0.29     Missed  -38.1
 Mar. 31 2021  -0.20       -0.22      -0.24     Missed  -9.1
 Dec. 31 2020  -0.23       -0.23      -0.18     Beat    21.7​
 Sep. 30 2020              -0.20      -0.19     Beat    4.2
 ​​Jun.        -0.23       -0.23      -0.18     Beat    20.6
 30 2020                                                
 Mar. 31 2020  -0.22       -0.22      -0.26     Missed  -16.9​
 Dec. 31 2019  -0.37       -0.32      -0.26     Beat    18.1
 Sep. 30 2019  -0.27       -0.28      -2.14     Missed  -673.5
 This summary was machine generated December 17 at 21:44 GMT. 
All figures in US dollars  unless otherwise stated